Skip to main content

Versant Venture Management, LLC

13F filer · CIK 0001560009
Reported Aug 12, 2026
Net seller this quarter
13F portfolio value$163MU.S. long equity reported on 13F
Positions80 new · 0 closed
Net flow last quarter-$11.9MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 12, 20268 positions
GLUEMonte Rosa Therapeutics, Inc.$77M47.34%3.73%Not reportedQ4 2024
IPSCCentury Therapeutics, Inc.$29.8M18.33%6.74%Not reportedQ1 2026
JBIOJade Biosciences, Inc.$22M13.55%1.56%-35.0%Q2 2025
LENZLENZ Therapeutics, Inc.$15.1M9.28%8.46%Not reportedQ3 2025
CTNMContineum Therapeutics, Inc.$8.89M5.47%2.35%Not reportedQ2 2024
CRSPCRISPR Therapeutics AG$8.12M4.99%0.15%Not reportedQ2 2018
SKYESkye Bioscience, Inc.$1.39M0.86%5.71%Not reportedQ1 2024
TPSTTempest Therapeutics, Inc.$299K0.18%1.69%Not reportedQ4 2024
Q1 2026Reported May 5, 20268 positions
GLUEMonte Rosa Therapeutics, Inc.$52.3M37.00%3.77%-27.4%Q4 2024
IPSCCentury Therapeutics, Inc.$27.5M19.44%6.76%NewQ1 2026
LENZLENZ Therapeutics, Inc.$24.3M17.19%8.47%Not reportedQ3 2025
JBIOJade Biosciences, Inc.$21.4M15.16%3.09%Not reportedQ2 2025
CTNMContineum Therapeutics, Inc.$7.09M5.01%2.35%Not reportedQ2 2024
CRSPCRISPR Therapeutics AG$7.08M5.01%0.15%Not reportedQ2 2018
SKYESkye Bioscience, Inc.$1.23M0.87%5.72%Not reportedQ1 2024
TPSTTempest Therapeutics, Inc.$442K0.31%1.88%Not reportedQ4 2024
Q4 2025Reported Feb 12, 20267 positions
GLUEMonte Rosa Therapeutics, Inc.$68.7M45.49%6.69%-22.5%Q4 2024
LENZLENZ Therapeutics, Inc.$42.5M28.14%8.48%Not reportedQ3 2025
JBIOJade Biosciences, Inc.$23.5M15.59%3.09%Not reportedQ2 2025
CRSPCRISPR Therapeutics AG$7.8M5.17%0.16%Not reportedQ2 2018
CTNMContineum Therapeutics, Inc.$6.2M4.11%2.35%Not reportedQ2 2024
SKYESkye Bioscience, Inc.$1.51M1.00%6.02%Not reportedQ1 2024
TPSTTempest Therapeutics, Inc.$774K0.51%5.48%Not reportedQ4 2024
Q3 2025Reported Nov 10, 20259 positions
LENZLENZ Therapeutics, Inc.$124M58.25%9.29%NewQ3 2025
GLUEMonte Rosa Therapeutics, Inc.$41.9M19.72%9.15%Not reportedQ4 2024
JBIOJade Biosciences, Inc.$13.2M6.20%4.68%Not reportedQ2 2025
CRSPCRISPR Therapeutics AG$9.65M4.54%0.16%-70.2%Q2 2018
SKYESkye Bioscience, Inc.$7.89M3.71%6.48%Not reportedQ1 2024
CTNMContineum Therapeutics, Inc.$6.38M3.00%1.94%Not reportedQ2 2024
RPTXRepare Therapeutics Inc.$4.66M2.19%6.16%Not reportedQ2 2023
TPSTTempest Therapeutics, Inc.$2.77M1.31%6.08%Not reportedQ4 2024
ADVMAdverum Biotechnologies, Inc.$2.3M1.08%2.42%Not reportedQ1 2020
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.